ABSTRACT
In terms of disease-specific survival, using the same approach (Table 7.10), liposarcoma has significantly improved 5-year survival, as does fibrosarcoma, whereas leiomyosarcoma and MPNT have worse 5-year disease-specific survival. This is all consistent with distant recurrence-free survival (Table 7.11), where the improvement in liposarcoma is seen and the poorer prognosis for leiomyosarcoma and MPNT identified. Because of the tendency of fibrosarcoma to recur locally rather than systemically, fibrosarcoma also has an improved distant relapse-free survival.
